Talk Title: Proteomics for signaling and clinical studies
Matthias Mann studied physics and mathematics at Göttingen University and obtained his Ph.D. in chemical engineering at Yale where he was decisively involved in the development of electrospray ionization. Thereafter at the University of Southern Denmark he developed the first bioinformatic search algorithms for peptide fragmentation data and SILAC, a new method of quantitative proteomics and a breakthrough in the mapping of protein interactions.
In 2005, he was appointed director at the Max-Planck Institute of Biochemistry in Munich. Here his group addresses a wide range of biological questions developing and using proteomic technology. In 2009 Dr. Mann was additionally appointed director at the NNF Center for Protein Research in Copenhagen.
He has been elected as a member of EMBO, the Royal Danish Academy of Arts and Sciences and the Leopoldina German National Academy of Sciences. In 2012 he was awarded the Leibniz Prize from the German Research Foundation, the Ernst Schering Prize, the Louis-Jeantet Foundation Prize for Medicine and the Körber European Science Prize. In 2015 was awarded the Barry L. Karger Medal in Bioanalytical Chemistry and the Theodor Bücher Lecture and Medal as well as the Danish Order of Dannebrog Knights Cross.
Abstract: Proteomics for signaling and clinical studies
Max-Planck Institute of Biochemistry, Munich and Novo Nordisk Foundation Center for Protein Research, Copenhagen
Mass spectrometry-based proteomics has become an indispensable part of biochemical science and is used in a wide variety of contexts (Aebersold and Mann, Nature, 2016). In this talk, I will focus on the latest improvements and application of phosphoproteomics as well as clinical proteomics. Building on the ‘EasyPhos’ method developed recently (Humphrey et al. Nat. Biotech, 2015), we are now studying complex signaling events in vivo. For instance, application of EasyPhos to the circadian rhythm has revealed that a large percentage of the phospho-proteomics is coordinately regulated during the day and night cycle, and many of the target sites appear to fine tune the metabolic machinery (Robles et al. Cell Metabolism, 2017). Ongoing work in our laboratory has unraveled signaling downstream events downstream of opioid receptors in the brain in the context of analgesia and addiction.
The plasma proteome represents one of the remaining challenges of proteomics and its efficient analysis would be of huge importance to medical diagnostics. We recently described the Protein Correlation Profiling approach, which allows us to study the plasma proteome rapidly in a wide range of conditions (Geyer et al. Cell Systems 2016). We have now drastically increased the protein coverage and applied it to a number of clinical studies (Geyer et al. MSB 2016). The talk will summarize what we have learned from these studies in the particular context of metabolic disease and about the nature of the plasma proteome in general.